Compare CYTK & HMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | HMY |
|---|---|---|
| Founded | 1997 | 1950 |
| Country | United States | South Africa |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.3B |
| IPO Year | 2004 | 2002 |
| Metric | CYTK | HMY |
|---|---|---|
| Price | $75.87 | $20.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 2 |
| Target Price | ★ $89.26 | $16.00 |
| AVG Volume (30 Days) | 1.8M | ★ 2.4M |
| Earning Date | 05-05-2026 | 02-04-2016 |
| Dividend Yield | N/A | ★ 2.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,368,000.00 | N/A |
| Revenue This Year | $7.37 | $37.43 |
| Revenue Next Year | $310.19 | $27.44 |
| P/E Ratio | ★ N/A | $15.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.22 | $13.03 |
| 52 Week High | $88.31 | $26.04 |
| Indicator | CYTK | HMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 70.16 |
| Support Level | $73.95 | $19.19 |
| Resistance Level | $80.65 | $21.62 |
| Average True Range (ATR) | 2.94 | 0.55 |
| MACD | -0.58 | 0.30 |
| Stochastic Oscillator | 26.45 | 98.70 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Harmony Gold Mining Co Ltd is engaged in gold mining and related activities, including exploration, extraction, and processing. The group's primary product is gold bullion, produced at operations in South Africa and Papua New Guinea. Gold byproducts include uranium and silver. Strategic projects such as the Wafi-Golpu Project in the New Guinea Mobile Belt, the Eva Copper Project in the Mt Isa Inlier, Queensland, Australia, and the MAC Copper acquisition position the company as a gold-copper producer. The company operates across South Africa, Papua New Guinea, and Australia.